Welcome to our dedicated page for Windtree Therapeutics news (Ticker: WINT), a resource for investors and traders seeking the latest updates and insights on Windtree Therapeutics stock.
Windtree Therapeutics, Inc. (WINT) generates news across biotechnology, licensing, financing and corporate diversification activities. Company press releases highlight its evolution from a biotechnology focus into a diversified business with several divisions and an emphasis on becoming a revenue generating company. For followers of WINT news, this means updates can span drug development milestones, asset sales, licensing income opportunities, environmental services initiatives, fintech transactions and capital markets activity.
In the biotech arena, Windtree’s news flow has included interim data and scientific presentations for its cardiovascular drug candidate istaroxime and related SERCA2a activators, as well as decisions to adjust or terminate specific clinical studies based on resources and strategic priorities. The company has also reported on strengthening its patent estate for these cardiovascular assets and later announced an agreement to sell its cardiovascular drug candidates to Seismic Pharmaceutical Holdings, LLC while retaining rights to a share of future proceeds and transferring certain development payables.
Windtree’s communications also cover its acute pulmonary franchise, where a global license agreement for RDS treatments such as SURFAXIN, lyophilized lucinactant and AEROSURF may generate milestone and royalty payments if development and commercialization progress under the licensee. Additional news items describe corporate strategy decisions, including a focus on environmental services and other revenue generating businesses, a letter of intent to acquire CommLoan, Inc. in the fintech and commercial real estate lending technology space, and the outcome of stockholder votes supporting financing flexibility.
Investors tracking WINT-related headlines will also see coverage of financing arrangements, preferred stock conversions, equity line of credit structures, and the company’s exploration of a BNB cryptocurrency treasury strategy, as well as its transition from the Nasdaq Capital Market to over-the-counter trading. Bookmarking this news feed can help readers monitor how Windtree’s mix of biotech assets, licensing agreements and diversified business initiatives evolves over time.
The company is pursuing a new strategy to become revenue-generating through: - Acquiring FDA-approved assets - A right to purchase a 436-unit residential property in Houston - Partnership for PHEXXI® manufacturing cost reduction - China partnership expected to generate revenues by end of 2026
Financial position shows cash and cash equivalents of $1.2 million with current liabilities of $6.5 million. The company raised $2.6 million through Series D convertible preferred stock in April-May 2025. Notably, Windtree regained Nasdaq compliance but remains under monitoring until March 2026.
Windtree Therapeutics (NASDAQ: WINT) announced the presentation of preclinical data on istaroxime and a selective SERCA2a activator at the upcoming European Society of Cardiology Heart Failure Conference. The ePoster presentation demonstrates how istaroxime and its metabolite analog (CVie216) help reduce calcium-dependent arrhythmias in an STZ rat model during ischemia-reperfusion by activating SERCA2a.
The study identified a potential mechanism explaining the decreased incidence of reperfusion-induced arrhythmias in STZ-isolated hearts after exposure to these compounds. This research is particularly significant as arrhythmias can severely impact heart function and can be fatal, especially in patients with heart failure and cardiomyopathy.
Windtree Therapeutics (NASDAQ: WINT) has announced potential U.S. exclusivity strategies for its drug candidate istaroxime in treating cardiogenic shock. If granted New Chemical Entity (NCE) designation by the FDA, istaroxime could receive 7.5 years of U.S. market exclusivity upon approval. The company also holds a U.S. method of use patent extending protection until 2039, with a pending patent that could provide coverage until 2043.
The company is currently conducting the SEISMiC C Phase 2 study, a global placebo-controlled trial evaluating istaroxime in SCAI Stage C cardiogenic shock patients. The study's primary endpoint focuses on systolic blood pressure profile over 6 hours of treatment, with an interim analysis planned for Q3 2025.
Windtree Therapeutics (WINT) has entered an Assignment and Conditional Assumption Agreement to acquire a 436-unit multifamily residential property in Houston, Texas. This strategic move marks a shift in the company's strategy to become revenue-generating while continuing its biotech pipeline development. The acquisition, planned for May 23, 2025, will be primarily funded through non-recourse secured mortgage financing and preferred stock issuance.
The company has the option to extend the closing date for two 30-day periods. The deal is contingent upon satisfactory due diligence and financing terms. Windtree's new corporate strategy includes acquiring revenue-generating assets, including small biotech companies with FDA-approved products, while maintaining its focus on cardiovascular and oncology drug development.
Windtree Therapeutics (WINT) reported its fiscal year 2024 results and key business updates. The company announced positive results from its Phase 2 SEISMiC Extension Study of istaroxime in early cardiogenic shock treatment and initiated the global SEISMiC C trial for more severe cases.
Financial highlights include R&D expenses of $16.3 million (up from $8.3 million in 2023) and reduced G&A expenses of $8.7 million (down from $9.2 million). The company reported a net loss of $1.8 million for 2024, significantly improved from a $20.3 million loss in 2023.
Key developments include a new corporate strategy to become revenue-generating through acquisitions of FDA-approved products, a licensing partnership with Lee's Pharmaceutical for Greater China, and patent developments for istaroxime. Cash position stands at $1.8 million as of December 31, 2024, with funding expected to last through April 2025.
Evofem Biosciences (OTCQB: EVFM) has entered into a License and Supply Agreement with Windtree Therapeutics (NasdaqCM: WINT) to reduce manufacturing costs of PHEXXI, their FDA-approved hormone-free contraceptive vaginal gel. The partnership is expected to decrease PHEXXI's manufacturing costs by 55% to 60% from current levels, with no tech transfer costs to Evofem.
PHEXXI, which prevents pregnancy by maintaining normal vaginal pH levels inhospitable to sperm, will benefit from Windtree's manufacturing contacts to achieve lower production costs. This cost reduction aims to facilitate PHEXXI's global expansion into price-sensitive markets where non-hormonal contraceptives are in demand.
Evofem maintains ownership and continues U.S. commercialization through its sales team, while pursuing international expansion through strategic partnerships, including a July 2024 license agreement with Pharma 1 Drug Store for UAE market entry.
Evofem Biosciences (OTCQB: EVFM) reported its financial results for Q4 and full-year 2024, marking its fourth consecutive year of net sales growth. The company achieved $19.4 million in net sales for 2024, a 6% increase from 2023, primarily driven by PHEXXI® sales and improved gross-to-net ratio.
Key operational highlights include:
- Total operating expense reduced by 27% to $26.4 million (excluding SOLOSEC amortization)
- Sales and marketing expense at 47% of net sales for 2024, the best ratio since PHEXXI's launch
- Loss from operations improved by 57% to $7.7 million
- Revenue stream diversified through SOLOSEC® acquisition in July 2024
The company entered a fifth amendment to the merger agreement with Aditxt (NASDAQ: ADTX), requiring $1.5 million funding by April 7, 2025, and merger consummation by September 30, 2025. Additionally, Evofem partnered with Windtree Therapeutics to reduce PHEXXI manufacturing costs.
Windtree Therapeutics (WINT) has successfully regained compliance with Nasdaq's minimum bid price requirement, following a notice of non-compliance received on December 4, 2024. The biotechnology company, which focuses on developing innovative therapies for critical conditions, had failed to maintain a closing bid price of $1.00 or more for 30 consecutive trading days.
To regain compliance, WINT needed to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. The company achieved this requirement, maintaining the required bid price since February 21, 2025. Windtree will remain under a mandatory panel monitor until March 20, 2026.
FAQ
What is the current stock price of Windtree Therapeutics (WINT)?
What is the market cap of Windtree Therapeutics (WINT)?
